{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:13:16Z","timestamp":1784211196781,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112784","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:33:22Z","timestamp":1784208802000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Susceptibility of Methicillin-Resistant Staphylococcus aureus Isolates to Ceftaroline and Other Antistaphylococcal Agents"],"prefix":"10.7759","author":[{"given":"Rishabh","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniya","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner NA","year":"2019","unstructured":"Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al.. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019, 17:203-18. 10.1038\/s41579-018-0147-4","journal-title":"Nat Rev Microbiol"},{"key":"ref2","article-title":"Methicillin-resistant Staphylococcus aureus infections","volume":"16","author":"Bartlett JG","year":"2008","unstructured":"Bartlett JG. Methicillin-resistant Staphylococcus aureus infections. Top HIV Med. 2008, 16:151-5.","journal-title":"Top HIV Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1021\/bi990025e","article-title":"Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with beta-lactams using electrospray mass spectrometry","volume":"38","author":"Lu WP","year":"1999","unstructured":"Lu WP, Sun Y, Bauer MD, Paule S, Koenigs PM, Kraft WG. Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with beta-lactams using electrospray mass spectrometry. Biochemistry. 1999, 38:6537-46. 10.1021\/bi990025e","journal-title":"Biochemistry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S17432","article-title":"Ceftaroline in complicated skin and skin-structure infections","volume":"5","author":"Hernandez PO","year":"2012","unstructured":"Hernandez PO, Lema S, Tyring SK, Mendoza N. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist. 2012, 5:23-35. 10.2147\/IDR.S17432","journal-title":"Infect Drug Resist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1289","article-title":"Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus","volume":"66","author":"Fishovitz J","year":"2014","unstructured":"Fishovitz J, Hermoso JA, Chang M, Mobashery S. Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. IUBMB Life. 2014, 66:572-7. 10.1002\/iub.1289","journal-title":"IUBMB Life"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S33430","article-title":"An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy","volume":"7","author":"Watkins RR","year":"2012","unstructured":"Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012, 7:131-43. 10.2147\/CE.S33430","journal-title":"Core Evid"},{"key":"ref7","article-title":"Comparative efficacy of ceftaroline with linezolid against Staphylococcus aureus and methicillin resistant Staphylococcus aureus","volume":"25","author":"Hafeez A","year":"2015","unstructured":"Hafeez A, Munir T, Rehman S, et al.. Comparative efficacy of ceftaroline with linezolid against Staphylococcus aureus and methicillin resistant Staphylococcus aureus. J Coll Physicians Surg Pak. 2015, 25:247-9.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/45.4_ts.493","article-title":"Antibiotic susceptibility testing by a standardized single disk method","volume":"45","author":"Bauer AW","year":"1966","unstructured":"Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966, 45:493-6.","journal-title":"Am J Clin Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5243-5246.2005","article-title":"Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole","volume":"43","author":"Espinel-Ingroff A","year":"2005","unstructured":"Espinel-Ingroff A, Fothergill A, Ghannoum M, et al.. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005, 43:5243-6. 10.1128\/JCM.43.10.5243-5246.2005","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel GG","year":"2009","unstructured":"Zhanel GG, Sniezek G, Schweizer F, et al.. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009, 69:809-31. 10.2165\/00003495-200969070-00003","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S226649","article-title":"In vitro activity of ceftaroline and comparators against Staphylococcus aureus isolates: results from 6 years of the ATLAS program (2012 to 2017)","volume":"12","author":"Zhang Z","year":"2019","unstructured":"Zhang Z, Chen M, Yu Y, Liu B, Liu Y. In vitro activity of ceftaroline and comparators against Staphylococcus aureus isolates: results from 6 years of the ATLAS program (2012 to 2017). Infect Drug Resist. 2019, 12:3349-58. 10.2147\/IDR.S226649","journal-title":"Infect Drug Resist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49859","article-title":"Evaluation of in-vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus clinical isolates","volume":"15","author":"Roy A","year":"2023","unstructured":"Roy A, Poddar N, Panigrahi K, et al.. Evaluation of in-vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus clinical isolates. Cureus. 2023, 15:e49859. 10.7759\/cureus.49859","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/ijm\/4558662","article-title":"Ceftaroline exhibits promising in vitro activity against methicillin-resistant Staphylococcus aureus clinical isolates from Alexandria, Egypt","volume":"2025","author":"Sallam HH","year":"2025","unstructured":"Sallam HH, Ramadan AA, Attia NM, ElBaradei A, Shawky SM, El-Kholy MA. Ceftaroline exhibits promising in vitro activity against methicillin-resistant Staphylococcus aureus clinical isolates from Alexandria, Egypt. Int J Microbiol. 2025, 2025:4558662. 10.1155\/ijm\/4558662","journal-title":"Int J Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2025.46.8.20241078","article-title":"Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus (MRSA) infections in a tertiary care hospital in Saudi Arabia: an 8-year retrospective analysis","volume":"46","author":"Alhazmi JS","year":"2025","unstructured":"Alhazmi JS, Al-Khaldi AS, Kaabia NM, Bouafia NA, Mohammed YK, Al Garni MA, Odayani AN. Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus (MRSA) infections in a tertiary care hospital in Saudi Arabia: an 8-year retrospective analysis. Saudi Med J. 2025, 46:891-7. 10.15537\/smj.2025.46.8.20241078","journal-title":"Saudi Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1775-x","article-title":"Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis","volume":"71","author":"Wang Y","year":"2015","unstructured":"Wang Y, Zou Y, Xie J, et al.. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015, 71:107-15. 10.1007\/s00228-014-1775-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato H","year":"2021","unstructured":"Kato H, Hagihara M, Asai N, Shibata Y, Koizumi Y, Yamagishi Y, Mikamo H. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021, 24:98-105. 10.1016\/j.jgar.2020.12.009","journal-title":"J Glob Antimicrob Resist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040697","article-title":"Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"12","author":"Kawasuji H","year":"2023","unstructured":"Kawasuji H, Nagaoka K, Tsuji Y, et al.. Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Antibiotics (Basel). 2023, 12:697. 10.3390\/antibiotics12040697","journal-title":"Antibiotics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511616-assessment-of-susceptibility-of-methicillin-resistant-staphylococcus-aureus-isolates-to-ceftaroline-and-other-antistaphylococcal-agents","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:33:23Z","timestamp":1784208803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511616-assessment-of-susceptibility-of-methicillin-resistant-staphylococcus-aureus-isolates-to-ceftaroline-and-other-antistaphylococcal-agents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.112784","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}